Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568

Hepatitis C, Chronic

COMPLETED PHASE3

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

NCT01508130

Hepatitis C, Chronic

COMPLETED

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT00516321

Hepatitis C, Chronic

COMPLETED PHASE3

Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir

NCT01582035

Hepatitis C

COMPLETED PHASE1

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

NCT01485991

Hepatitis C

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study had three phases: Prerandomization (Screening), Randomization (Core Study), and Open-Label Extension (OLE). The Randomization Phase included Treatment Periods A1 and A2 and a Follow-up Period (for those participants not continuing into the OLE phase). The OLE Phase included Treatment Periods B1, B2, and B3 (depending on when a participant entered the OLE), and a Follow-up Period. Participants may have been followed for sustained viral response, if appropriate. In the Core Study (randomization phase) participants were randomized (in a 1:1:1:1 ratio) to receive one of four treatments (placebo or avatrombopag \[10mg, 20mg, and 30mg\] for up to 21 days. Participants who successfully completed Treatment Period A1, (platelet count \>=100x10\^9/L) initiated antiviral treatment with pegylated interferon (PEG-IFN) alpha-2a and progressed to Treatment Period A2. Participants with a platelet count \>=150x10\^9/L initiated antiviral treatment and progressed into Treatment Period B2, study drug was interrupted then eventually restarted at 10 mg daily once their platelet counts returned to acceptable levels. Those who were not considered successful after 21 days in Treatment Phase A1 were withdrawn from the Core Study (Part A) and were eligible to enter the OLE at Treatment Period B1. Participants who chose to not enter the OLE entered into the Follow-up Phase. At the end of Treatment Period A2, eligible participants could enter the OLE at Treatment Period B3. In the OLE Phase, participants entering into Open-label Treatment Period B1 began once-daily treatment with avatrombopag at a dose of 20 mg without titration for up to 21 days. Once the participant's platelet counts were sufficient, they entered Treatment Period B2. Participant's eligible to enter into Treatment Period B2 received avatrombopag and antiviral treatment for 13 weeks. Participants who successfully completed Treatment Period A2 or B2 could continue on antiviral treatment for up to a maximum of 48 weeks (including the 13 weeks in Treatment Periods A2 or B2) and open-label avatrombopag, at the investigator's discretion. In Treatment Period B3, the dose of avatrombopag was allowed to be titrated up or down in accordance with the participant's platelet count response, within the range of a minimum of 5 mg and a maximum of 50 mg. In the Follow-up Period, participants were seen at either a single 30-day follow-up visit or followed for the full 30 days after the last dose of avatrombopag.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombocytopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo (Core Study)

Placebo, will be administered orally, once daily for up to 21 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Avatrombopag 10 mg (Core Study)

Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.

Group Type ACTIVE_COMPARATOR

Avatrombopag

Intervention Type DRUG

Avatrombopag 20 mg (Core Study)

Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.

Group Type ACTIVE_COMPARATOR

Avatrombopag

Intervention Type DRUG

Pegylated interferon (PEG-IFN)

Intervention Type DRUG

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.

Telaprevir

Intervention Type DRUG

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Ribavirin

Intervention Type DRUG

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Avatrombopag 30 mg (Core Study)

Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.

Group Type ACTIVE_COMPARATOR

Avatrombopag

Intervention Type DRUG

Avatrombopag (Open-Label Extension)

Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.

Group Type EXPERIMENTAL

Avatrombopag

Intervention Type DRUG

Pegylated interferon (PEG-IFN)

Intervention Type DRUG

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.

Telaprevir

Intervention Type DRUG

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Ribavirin

Intervention Type DRUG

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avatrombopag

Intervention Type DRUG

Placebo

Intervention Type DRUG

Pegylated interferon (PEG-IFN)

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.

Intervention Type DRUG

Telaprevir

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Intervention Type DRUG

Ribavirin

Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

E5501 Avatrombopag maleate Incivek Incivo Virazole Rebetol Copegus Ribasphere Moderiba dose pack Moderiba

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females greater than or equal to 18 years of age
2. Women of childbearing potential must agree to use a highly effective method of contraception for at least one menstrual cycle prior to starting study drug, throughout the entire study period, and for 30 days after the last dose of study drug
3. Subjects with chronic HCV-related thrombocytopenia (defined as a platelet count greater than or equal to 20x10\^9/L to 70x10\^9/L) who require antiviral treatment
4. Chronic HCV infection (defined as the presence of anti-HCV antibodies and detectable serum HCV RNA levels)
5. Model for End-stage Liver disease score greater than or equal to 24
6. Adequate renal function as evidenced by a calculated creatinine clearance greater than or equal to 50 mL/minute per the Cockcroft and Gault formula
7. Life expectancy greater than or equal to 3 months

Exclusion Criteria

1. Any history of arterial or venous thrombosis, including partial or complete thrombosis (e.g., stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism), thrombosis (partial or complete) in the main portal vein and portal vein branches, and thrombosis of any part of the splenic-mesenteric system
2. Any evidence of current portal vein thrombosis (PVT) as detected by Doppler sonography and portal vein flow rate less than 15 cm/second at Screening or within 30 days prior to Screening (revised per Amendment 02)
3. Any known family history of hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency)
4. Evidence of myocardial infarction in the last 6 months or uncompensated congestive heart failure (New York Heart Association Class III or IV)
5. Co-infection with human immunodeficiency virus (HIV) or hepatitis B or acute hepatitis C
6. Any prohibited concomitant medications or therapy that cannot be discontinued by Visit 1, e.g., subjects currently receiving interferon who cannot undergo a 4-week washout period prior to Screening, or subjects who receive blood products that affect platelet count within 1 week prior to Screening (revised per Amendment 02)
7. Weekly alcohol intake greater than 21 units (168 g) \[male\] and greater than 14 units (112 g) \[female\]
8. Any known medical condition, other than chronic liver disease, that can lead to thrombocytopenia
9. History of hepatocellular carcinoma, metastatic liver cancer, or liver transplantation (revised per Amendment 01) (revised per Amendment 02)
10. History of idiopathic thrombocytopenic Purpura (ITP)
11. History of myelodysplastic syndrome
12. History of pernicious anemia or subjects with vitamin B12 deficiency (defined as less than the lower limit of normal \[LLN\]) who have not had pernicious anemia excluded as a cause (Added per Amendment 02)
13. Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that, in the opinion of the investigator, could affect the subject's safety or study conduct
14. Subjects with a history of suicide attempts
15. Subjects with a history of hospitalization for depression within the past 5 years
16. Subjects with any current severe or poorly controlled psychiatric or seizure disorder
17. Current use of recreational drugs
18. Subjects who have participated in another investigational study within 30 days prior to Visit 1
19. Subjects with hypersensitivity, intolerance, or allergy to E5501 or any anti-HCV therapies or their ingredients
20. Any past or current (revised per Amendment 01) medical condition that, in the opinion of the investigator, would compromise the subject's ability to safely complete the study
21. Scheduled for surgery during the projected course of the study
22. Subjects who have any medical conditions or diseases that would contraindicate treatment with anti-HCV therapy (added per Amendment 01)
23. Subjects who are currently treated with proton pump inhibitors (PPIs) or H2-antagonist therapy but have not been receiving a stable dose for at least 6 weeks prior to randomization or have not completed these therapies more than 2 weeks prior to randomization (added per Amendment 01)
24. Fasting gastrin-17 blood levels exceeding 1.5 times the upper limit of normal (ULN) at Screening (including subjects on PPIs or H2 antagonists) (revised per Amendment 02)
25. Subjects with a history of gastric atrophy (added per Amendment 02)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No